Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Parkinson Disease 4”

318 trials

Showing 20 of 318 results

Large-scale testing (Phase 3)Looking for participantsNCT06989112
What this trial is testing

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Who this might be right for
Endometrial Cancer
AstraZeneca 600
Not applicableStudy completedNCT03247387
What this trial is testing

EOnOff - D1 Extension

Who this might be right for
Parkinson Disease
Boston University 34
Post-approval studies (Phase 4)Study completedNCT05312632
What this trial is testing

Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Who this might be right for
Parkinson Disease
Eisai Korea Inc. 201
Early research (Phase 1)Study completedNCT02054806
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)

Who this might be right for
Solid Tumor
Merck Sharp & Dohme LLC 477
Testing effectiveness (Phase 2)Study completedNCT03631407
What this trial is testing

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Who this might be right for
Colorectal Neoplasms
Merck Sharp & Dohme LLC 41
Post-approval studies (Phase 4)Study completedNCT04821687
What this trial is testing

Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD

Who this might be right for
Parkinson Disease
SK Chemicals Co., Ltd. 169
Early research (Phase 1)Study completedNCT01964573
What this trial is testing

Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects

Who this might be right for
Parkinson's Disease
UCB Pharma 48
Large-scale testing (Phase 3)Active Not RecruitingNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 480
Early research (Phase 1)Study completedNCT04208152
What this trial is testing

A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects

Who this might be right for
Healthy Volunteers
MODAG GmbH 68
Early research (Phase 1)Study completedNCT01532115
What this trial is testing

Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women

Who this might be right for
Parkinson Disease
Bial - Portela C S.A. 64
Early research (Phase 1)Study completedNCT02728947
What this trial is testing

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Who this might be right for
Parkinson's Disease
Luye Pharma Group Ltd. 28
Large-scale testing (Phase 3)Active Not RecruitingNCT03711032
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Who this might be right for
High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC 1,397
Not applicableUnknownNCT04886193
What this trial is testing

FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis

Who this might be right for
ChemotherapyGastric Cancer
Guangdong Provincial Hospital of Traditional Chinese Medicine 20
Large-scale testing (Phase 3)Active Not RecruitingNCT03553836
What this trial is testing

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 976
Large-scale testing (Phase 3)Study completedNCT01866319
What this trial is testing

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 834
Not applicableUnknownNCT03917537
What this trial is testing

WGA in Platinum-refractory HNSCC Underwent Nivolumab

Who this might be right for
HNSCC
Chang Gung Memorial Hospital 80
Large-scale testing (Phase 3)Active Not RecruitingNCT04662710
What this trial is testing

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Who this might be right for
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Merck Sharp & Dohme LLC 895
Testing effectiveness (Phase 2)Study completedNCT02255097
What this trial is testing

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 172
Large-scale testing (Phase 3)Active Not RecruitingNCT05899049
What this trial is testing

Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 249
Large-scale testing (Phase 3)Study completedNCT03361865
What this trial is testing

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

Who this might be right for
UC (Urothelial Cancer)
Incyte Corporation 93
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation